English translation of the original Korean article: 통풍 신약 ‘에파미뉴라드’, 아시아 임상 3상서 표준치료제보다 우수한 효과 확인 South Korean pharmaceutical company JW Pharmaceutical announced on August 11 that its investigational gout drug candidate ‘Epaminurad’ (URC102) demonstrated superior uric-acid-lowering efficacy compared to the standard treatment in a multinational Phase 3 trial…